NEW YORK — Alzpath said on Monday that it has licensed a proprietary Alzheimer's disease biomarker to Siemens Healthineers for use in an assay for the brain disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback